Marc J Chapdelaine

US Patent:

6812225, Nov 2, 2004

Filed:

Jan 16, 2002

Appl. No.:

10/051776

Inventors:

Edward Pierson - Wilmington DE
Daniel Sohn - Sodertalje, SE
Markus Haeberlein - Sodertalje, SE
Timothy Davenport - Wilmington DE
Marc Chapdelaine - Wilmington DE
Carey Horchler - Wilmington DE
John P. McCauley - Wilmington DE

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

A61K 3137

US Classification:

514183, 514456, 514430, 549 23, 549362, 549396, 549406, 549407

Abstract:

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT and 5HT antagonists.

US Patent:

6815447, Nov 9, 2004

Filed:

Oct 2, 2003

Appl. No.:

10/415785

Inventors:

Bipinchandra Chaudhari - Wilmington DE
Marc Chapdelaine - Wilmington DE
Greg Hostetler - Newark DE
Lucius Kemp - Philadelphia PA
John McCauley - Wilmington DE

Assignee:

Astrazeneca AB - Sodertalje

International Classification:

C07D40112

US Classification:

514275, 544324

Abstract:

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R , R and R are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.

US Patent:

6841680, Jan 11, 2005

Filed:

Oct 31, 2001

Appl. No.:

10/415783

Inventors:

Marc Chapdelaine - Wilmington DE, US
Lucius Kemp - Philadelphia PA, US
John McCauley - Wilmington DE, US

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

A61K 3147
C07D21522

US Classification:

546159, 546160, 546161, 514313

Abstract:

Compounds having selective action at neuronal N-type calcium channels useful for the treatment of pain in accord with the following structural diagram, wherein R, Rand Rare a variety of groups as defined in the specification.

US Patent:

6906193, Jun 14, 2005

Filed:

Oct 31, 2001

Appl. No.:

10/415774

Inventors:

Glen Ernst - Wilmington DE, US
Marc Chapdelaine - Wilmington DE, US
Dannielle Kissel - Boothwyn PA, US
Greg Hostetler - Newark DE, US
John McCauley - Wilmington DE, US

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

C07D215/38
C07D215/44
A61K031/60

US Classification:

546159, 546152, 514313, 514159, 514160

Abstract:

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R, R, R, Rand Rare any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

US Patent:

6939896, Sep 6, 2005

Filed:

Dec 18, 2000

Appl. No.:

10/168475

Inventors:

Marc Jerome Chapdelaine - Wilmington DE, US
Katherine Knappenberger - Wilmington DE, US
Gary Steelman - Wilmington DE, US
Suzanne Suchard - Wilmington DE, US
Linda Sygowski - Wilmington DE, US
Rebecca Urbanek - Wilmington DE, US
Chris Allan Veale - Wilmington DE, US

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

A61K031/22
C07C050/10
C07C050/12

US Classification:

514682, 552292

Abstract:

Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Qat each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C-C) alkyl and C(O)phenyl, and Qis selected from hydrogen, halogen, O—(C-C)alkyl, O—(C-C)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NOor halogen, and indolyl may be substituted with (C-C)alkyl or phenyl.

US Patent:

7026314, Apr 11, 2006

Filed:

Jan 15, 2002

Appl. No.:

10/466449

Inventors:

Marc Chapdelaine - Wilmington DE, US
Timothy Davenport - Wilmington DE, US
Markus Haeberlein - Södertälje, SE
Carey Horchler - Wilmington DE, US
John McCauley - Wilmington DE, US
Edward Pierson - Wilmington DE, US
Daniel Sohn - Södertälje, SE

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

C07D 403/04
C07D 403/14
A61K 31/496
A61P 25/24
A61P 3/04

US Classification:

5142282, 5142335, 514241, 51425211, 51425305, 51425306, 51425311, 5142531, 51425403, 51425405, 51425406, 51425409, 51425401, 51425411, 514218, 544 62, 544121, 544180, 544357, 544360, 544362, 544363, 544368, 544369, 544370, 544371, 544372, 544373, 544376, 540575

Abstract:

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTantagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

US Patent:

7045514, May 16, 2006

Filed:

Jul 12, 2004

Appl. No.:

10/889350

Inventors:

Edward Pierson - Wilmington DE, US
Daniel Sohn - Sodertalje, SE
Markus Haeberlein - Sodertalje, SE
Timothy Davenport - Wilmington DE, US
Marc Chapdelaine - Wilmington DE, US
Carey Horchler - Wilmington DE, US
John P. McCauley - Wilmington DE, US

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

A61K 31/33
A61K 31/38
A61K 31/35
C07D 335/04
C07D 311/04

US Classification:

514183, 514456, 514430, 549 23, 549362, 549396, 549406, 549407

Abstract:

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

US Patent:

7189714, Mar 13, 2007

Filed:

Oct 31, 2001

Appl. No.:

10/415853

Inventors:

Marc Chapdelaine - Wilmington DE, US
Lucius Kemp - Philadelphia PA, US
John McCauley - Wilmington DE, US

Assignee:

Astrazeneca AB - Sodertalje

International Classification:

A61K 31/5377
A61K 31/506
A61K 31/472
A61K 31/4725
C07D 265/30
C07D 239/04

US Classification:

5142335, 5142358, 5142368, 514256, 514313, 544128, 544149, 544152, 544333, 546159

Abstract:

Compounds useful for the treatment of pain in accord with the following structural diagram,.